The ABCs Of mRNA Vaccines

The ABCs Of mRNA Vaccines

News of positive data from Moderna’s (Cambridge, MA) Phase I trial of a COVID-19 vaccine has dominated this week’s headlines. Their vaccine is an mRNA-based vaccine—an entirely new approach to not only vaccines but also to therapeutics.  mRNA-based drugs...
Neoantigen Cancer Vaccines

Neoantigen Cancer Vaccines

The Elusive Cancer Vaccine Like unicorns, the fountain of youth and calorie-free chocolate, cancer vaccines have long proven elusive. But the emergence of a new crop of biotech companies makes it clear that a cancer vaccine is no myth. The latest advances in genomics...
PARP1 Inhibitor Takes On Pancreatic Cancer

PARP1 Inhibitor Takes On Pancreatic Cancer

PARP1 INHIBITORs PARP1 inhibitors are back in the headlines this week, as Astra Zeneca’s (Cambridge, England) and Merck’s (Kenilworth, New Jersey) Lynparza posted positive Phase III results from a trial with pancreatic cancer patients—a notoriously difficult...
Therapeutic Antibody Primer

Therapeutic Antibody Primer

Basics & Innovations Monoclonal antibody (mAb) therapeutics burst onto the healthcare scene 20 years ago, and today they remain one of the most versatile and effective therapeutics available. The tried and true mAbs are still in high demand, and we suspect this...
Post-translational Modifications In Biotech

Post-translational Modifications In Biotech

Basic Science Meets Application “Post-translational modification” may not be a term you hear every day, but it is critically important to the biotech industry—from understanding how cancer develops to producing biologics. Breaking the term down, we know that: “post”...